Feedback / Questions
precemtabart tocentecan (M9140) - EMD Serono
M9140: Data from dose expansion part of P1b PROCEADE-CRC-01 trial (NCT05464030) for colorectal cancer in Q2 2025
(EMD Serono)
-
Apr 3, 2025 -
Q4 2024 Results
P1 data
•
Colorectal Cancer • Oncology • Solid Tumor
https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2024-q4/en/2024-Q4-Earnings-Presentation-EN.pdf
Apr 3, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious